# Acquisition of the T790M resistance mutation during afatinib treatment in EGFR tyrosine kinase inhibitor–naïve patients with non–small cell lung cancer harboring *EGFR* mutations

SUPPLEMENTARY MATERIALS

Supplementary Figure 1: Relation of patient characteristics (smoking status, sex, age, and PS) to the emergence of T790M. *P* values were calculated with the chi-square test.

Supplementary Figure 2: Relation of dose reduction for afatinib to the emergence of T790M **(A)** or to PFS after the onset of afatinib treatment **(B).** Error bars in (B) indicate median ± quartile deviation. The P values were calculated with the chi-square test (A) or Student's t test (B).